Clinical significance of kininogen 1 expression in non-small cell lung cancer biofluids and tissues

doi:10.3969/j.issn.1006-7795.2021.01.013

Abstract

Abstract: Objective To evaluate the clinical significance in the diagnosis and prognosis of non-small cell lung cancer (NSCLC) by detecting the expression of kininogen-1 (KNG1) in plasma, alveolar lavage fluid, urine and tissues of patients with NSCLC. Methods The plasma, alveolar lavage fluid and urine samples were collected from 40 patients with NSCLC and 20 patients with benign lung disease (as control group). Enzyme-linked immunosorbent assay was used to detect the content of KNG1 in plasma, bronchoalveolar lavage fluid (BALF) and urine. The expression of KNG1 in 40 NSCLC and its paracancerous control samples was detected by immunohistochemistry. Results The levels of KNG1 in plasma, BALF and urine of patients with NSCLC were significantly higher than those of the control group. Receiver operating characteristic (ROC) curve analysis showed that KNG1 had an area under curve (AUC) of 0.79, 0.89 and 0.87 in plasma, BALF, and urine respectively. All had statistical significance (P<0.05), indicating that KNG1 of each specimen had certain ability to diagnose NSCLC. The diagnostic cut-off values were 1 653.6 mg/L for plasma, 52.1 mg/L for BALF and 2.3 mg/L for urine. The results showed that the consistency of urine was the highest (Kappa=0.59), indicating that the diagnostic effect was better than plasma and BALF. Immunohistochemical staining of 40 NSCLC and adjacent normal tissues showed that KNG1 was higher in NSCLC tissues than in adjacent normal tissues. Conclusions KNG1 was highly expressed in plasma, alveolar lavage fluid, urine and tissues of NSCLC, and had a certain ability to diagnose NSCLC in body fluids, especially urine.

Key words: non-small cell lung cancer, kininogen 1, urine, bronchoalveolar lavage fluid(BALF), tissue

CLC Number:

R734.2

Wang Weiwei, Wang Shanshan, Zhang Man. Clinical significance of kininogen 1 expression in non-small cell lung cancer biofluids and tissues[J]. Journal of Capital Medical University, 2021, 42(1): 77-82.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2021.01.013

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2021/V42/I1/77

References

[1] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2019[J]. CA: Cancer J Clin, 2019, 69(1): 7-34.
[2] Osmani L, Askin F, Gabrielson E, et al. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy[J]. Semin Cancer Biol, 2018, 52(Pt 1): 103-109.
[3] Wang W, Wang S, Zhang M. Identification of urine biomarkers associated with lung adenocarcinoma[J]. Oncotarget, 2017, 8(24): 38517-38529.
[4] Sim S Y, Choi Y R, Lee J H,et al. In-depth proteomic analysis of human bronchoalveolar lavage fluid toward the biomarker discovery for lung cancers[J]. Proteom Clin Appl, 2019, 13(5): e1900028.
[5] Sharp C N, Korte E A, Hosseineja D K, et al. ELISA-based detection of open reading frame protein 1 in patients at risk of developing lung cancer [J]. Clin Chim Acta, 2020, 507:1-6.
[6] Abdul-Rahman P S, Lim B K, Hashim O H. Expression of high-abundance proteins in sera of patients with endometrial and cervical cancers: analysis using 2-DE with silver staining and lectin detection methods [J]. Electrophoresis, 2007, 28(12): 1989-1996.
[7] Wang J, Wang X, Lin S, et al. Identification of kininogen-1 as a serum biomarker for the early detection of advanced colorectal adenoma and colorectal cancer [J]. PLoS One, 2013, 8(7): e70519.
[8] Yu J S, Chen Y T, Chiang W F, et al. Saliva protein biomarkers to detect oral squamous cell carcinoma in a high-risk population in Taiwan[J]. Proceed Natl Acad Sci U S A, 2016, 113(41): 11549-11554.
[9] Kay FU, Kandathil A, Batra K, et al. Revisions to the tumor, node,metastasis staging of lung cancer (8th edition): rationale, radiologic findings and clinical imply cations[J]. World J Radiol, 2017, 9(6): 269-279.
[10]Yu S, Meng Q, Hu H, et al. Correlation of ANXA1 expression with drug resistance and relapse in bladder cancer[J]. Int J Clin Exp Pathol, 2014, 7(9): 5538-5548.
[11]Doustjalali S R, Yusof R, Yip C H, et al. Aberrant expression of acute-phase reactant proteins in sera and breast lesions of patients with malignant and benign breast tumors [J]. Electrophoresis, 2004, 25(14): 2392-2401.
[12]Mu A K, Lim B K, Hashim O H, et al. Identification of O-glycosylated proteins that are aberrantly excreted in the urine of patients with early stage ovarian cancer [J]. Int J Mol Sci, 2013, 14(4): 7923-7931.
[13]Sandim V, Pereira Dde A, Kalume D E, et al. Proteomic
analysis reveals differentially secreted proteins in the urine from patients with clear cell renal cell carcinoma [J]. Urol Oncol, 2016, 34(1): e11-e25.
[14]Xu J, Fang J, Cheng Z, et al. Overexpression of the Kininogen-1 inhibits proliferation and induces apoptosis of glioma cells[J]. J Exp Clin Cancer Res, 2018, 37(1): 180.
[15]Schrodter S, Braun M, Syring I, et al. Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma[J]. Mol Cancer, 2016, 15: 10.
[16]Jiang W, Zhang L, Guo Q, et al. Identification of the pathogenic biomarkers for hepatocellular carcinoma based on RNA-seq analyses[J]. Pathol Oncol Res, 2019, 25(3):1207-1213.
[17]Liu W, Liu B, Cai Q, et al. Proteomic identification of serum biomarkers for gastric cancer using multi-dimensional liquid chromatography and 2D differential gel electrophoresis [J]. Clin Chim Acta, 2012, 413(13-14): 1098-1106.
[18]Quesada-Calvo F, Massot C, Bertrand V, et al. OLFM4, KNG1 and Sec24C identified by proteomics and immunohistochemistry as potential markers of early colorectal cancer stages [J]. Clin Proteomics, 2017, 14: 9.
[19]Gao B, Yu T, Xue D, et al. A multidimensional integration analysis reveals potential bridging targets in the process of colorectal cancer liver metastasis [J]. PLoS One, 2017, 12(6): e0178760.
[20]Navaneethan U, Lourdusamy V, Gk Venkatesh P, et al. Bile proteomics for differentiation of malignant from benign biliary strictures: a pilot study[J]. Gastroenterol Rep, 2015, 3(2): 136-143.
[21]Huang D, Yuan W, Li H, et al. Identification of key pathways and biomarkers in sorafenib-resistant hepatocellular carcinoma using bioinformatics analysis [J]. Exp Ther Med, 2018, 16(3): 1850-1858.